A5021108113- Sarcoma Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Ovarian cancer diagnosis and treatment
- Advanced Breast Cancer Therapies
- Cancer Cells and Metastasis
- Colorectal Cancer Treatments and Studies
- Lymphoma Diagnosis and Treatment
- Cancer Diagnosis and Treatment
- Tumors and Oncological Cases
- Lung Cancer Treatments and Mutations
- Breast Cancer Treatment Studies
- Endometrial and Cervical Cancer Treatments
- Testicular diseases and treatments
- Monoclonal and Polyclonal Antibodies Research
- Pharmaceutical Economics and Policy
- Metastasis and carcinoma case studies
- Lung Cancer Research Studies
- Peptidase Inhibition and Analysis
- Occupational and environmental lung diseases
- Cardiac tumors and thrombi
- PI3K/AKT/mTOR signaling in cancer
- Health Systems, Economic Evaluations, Quality of Life
National Cancer Center Hospital East
2013-2024
National Cancer Center
2017-2024
Tokyo National Hospital
2018-2023
Pharmaceuticals and Medical Devices Agency
2023
Center for Assessment
2022
Breast Cancer Care
2017-2021
Canberra Hospital
2021
Yazaki (United States)
2020
Weatherford College
2020
Tokyo Metropolitan Komagome Hospital
2008-2015
BackgroundThe presence of tumour-infiltrating lymphocytes (TILs) is a favourable prognostic factor in patients with early breast cancer. Programmed cell death-1 (PD-1) and its ligand PD-L1 are associated variety adverse features. The purpose this study was to clarify the relationships between TILs, PD-1 as well their implications cancer.MethodsWe investigated 180 cancer who received neoadjuvant chemotherapy underwent subsequent surgery for stage II–III invasive carcinoma 1999 2007. TIL...
Two cases of pediatric lung cancer (in 23-month-old and 6-year-old boys) resulting from mother-to-infant transmission uterine cervical tumors were incidentally detected during routine next-generation sequencing paired samples tumor normal tissue. Spontaneous regression some lesions in the first child slow growth mass second suggested existence alloimmune responses against transmitted tumors. Immune checkpoint inhibitor therapy with nivolumab led to a strong all remaining child. (Funded by...
Introduction: Next-generation sequencing (NGS) is commonly used in clinical practice to decide treatment based on genomic information. This study was performed optimize the proportion of actionable gene profiling and genetic alterations breast cancer at one centers Japan. Methods: Patients with who reported NGS results Japan from August 2019 December 2023 were retrospectively investigated by reviewing their electronic medical records. examined using OncoGuideTM NCC Oncopanel System,...
PIK 3 CA mutations are common activating associated with breast cancer (occurring in 20–30% of all cases) and potent predictive markers for responses to PI 3K inhibitors. Thus, it is important develop sensitive methods detect these mutations. We established a novel detection method using quenching probe ( QP ) system identify mutations, DNA from 309 tissues. In developmental cohort, we determined the optimal threshold human tumor 119 freshly frozen samples. found 96% concordance rate between...
Background Intimal sarcoma (InS) is an exceedingly rare neoplasm with unfavorable prognosis, for which new potentially active treatments are under development. We report on the activity of anthracycline‐based regimens, gemcitabine‐based and pazopanib in patients InS. Methods Seventeen reference centers Europe, United States, Japan contributed data to this retrospective analysis. Patients MDM2‐positive InS who were treated or between October 2001 January 2018 selected. Local pathological...
Telomerase reverse transcriptase (TERT) promoter mutations have been discovered in solid and hematological malignancies, where they reflect TERT activation cell-cycle progression. In melanoma, glioma, thyroid cancers, are associated with a poor prognosis. However, no studies evaluated the prevalence prognostic significance of breast cancer. We analyzed hotspot (C228T C250T) using direct sequencing DNA from 319 tumor tissues. also collected clinical data cases that were positive for...
Metaplastic breast carcinomas are rare and carry poor prognoses. They also more aggressive than other cancers known for their resistance to chemotherapy. Prolonged treatment with dabrafenib trametinib is a therapy malignant melanoma that improves the progression-free survival overall survival. Such molecular-targeted therapies being developed BRAF mutation, driver of melanoma. Case Presentation. A 57-year-old woman metaplastic cancer chemotherapy-refractory massive pleural effusion. After...
ATF1 , CREB1 and CREM which encode the CREB family of transcription factors, are fused with EWSR1 or FUS in human neoplasms, such as angiomatoid fibrous histiocytoma. EWSR1/FUS-CREB fusions have recently been reported a group malignant epithelioid tumors predilection to peritoneal cavity frequent cytokeratin expression. Here, we studied 8 cytokeratin-positive abdominal malignancies these for further characterization. The affected males (15 76 y old) presented intra-abdominal masses...
Anaplastic lymphoma kinase (ALK) rearrangement is a well-known driver oncogene in non-small-cell lung cancer and has also been identified other types of tumors. However, there limited evidence on the clinical response to ALK tyrosine inhibitors (TKIs), such as alectinib crizotinib, rare tumors with fusion. We evaluated therapeutic effect ALK-TKIs ALK-rearranged tumors.Between April 2012 2019, outcomes characteristics patients nonlung solid who received (alectinib and/or crizotinib) outside...
To investigate the efficacy and safety of pazopanib for recurrent or metastatic solitary fibrous tumor (SFT) in first- second-line settings.Patients histologically diagnosed with SFT at our hospital who received monotherapy inoperable disease between January 2013 November 2016 were eligible. We retrospectively investigated treatment outcomes according to lines assessed adverse events.Nine patients The median age was 67 years (range 42-81), 6 (66.7%) male. Four (50%) as treatment. According...
Triple-negative breast cancer (TNBC) is negative for hormone receptors and human epidermal growth factor receptor 2 (HER2). In stage I TNBC, adjuvant therapy or follow-up are performed according to risk factors, but clinical trial data scarce. recent years, it has been reported that HER2-low cases (1+/2+ in situ hybridization negative) have different prognoses than HER2-0 cases. However, the of recurrence factors this population TNBC not yet investigated.Herein, out 174 patients with who...
Abstract Prognostic value of hematologic indices and their association with the tumor microenvironment (TME) remain unclear in advanced soft tissue sarcoma (STS). We aimed to evaluate prognostic correlation TME status STS treated first-line doxorubicin (DXR) therapy. Clinical data three hematological indices, including lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio, neutrophil-to-lymphocyte were collected from 149 patients STS. The was pathologically examined by CD3, CD68,...
•Of 507 patients who underwent CGP, 12.2% received genomically matched therapies with a 32.3% ORR.•The PFS ratios (>1.3) were observed in 46.3% (19/41) of the evaluated patients.•Patients rare cancers benefited most from tumor mutation profiling.•Early-line treatments following profiling increase therapeutic benefit, irrespective type. BackgroundComprehensive genome (CGP) serves as guide for suitable cancer. However, little is known about impact timing and types cancer on benefit...
Trabectedin is used as a treatment for advanced-stage soft tissue sarcomas (STSs), particularly liposarcoma and leiomyosarcoma. Aside from its direct effect on tumor cells, trabectedin can affect the immune system in microenvironment. This study aimed to evaluate whether inflammatory biomarkers predict efficacy STSs.
Abstract Palbociclib combined with endocrine therapy is approved for treating patients hormone-receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer; however, data on palbociclib tamoxifen are limited. We investigated the efficacy and safety of palbociclib–tamoxifen in HR+/HER2− cancer. This double-blind phase 3 study included 184 women who were randomly assigned 1:1 to receive or placebo–tamoxifen. Pre/perimenopausal also received goserelin....
Human epidermal growth factor receptor-3 (HER3) is a member of the receptor family tyrosine kinases, and its overexpression associated with inferior prognosis in several cancers. However, it unclear whether HER3 expression status changes tumor tissue at recurrence. Therefore, this study aimed to evaluate between primary recurrent gynecological cancers.This retrospective used matched-pair tissues cancer patients initial diagnosis Immunohistochemical (IHC) scores 3 + or 2 were termed...
In Japan, for pharmaceutical products to be covered by public medical insurance, their efficacy and safety must first confirmed in clinical trials. To our knowledge, this study is the investigation into off-label use of at a high-volume cancer treatment center Japan. The objective explore framework necessary future development regulatory approval field oncology surveying frequency indications National Cancer Center Hospital Tokyo, Japan.The used daily practice from 2003 2015 were...
Eribulin or capecitabine monotherapy is the next cytotoxic chemotherapy option for patients with metastatic recurrent breast cancer who have previously received an anthracycline a taxane. However, it unclear what factors can guide selection of eribulin in this setting, and prognostic are needed to appropriate treatment selection. The neutrophil-to-lymphocyte ratio (NLR) factor eribulin-treated patients, although whether capecitabine-treated patients. Therefore, we analysed ability NLR...
Abstract Purpose Stromal tumor-infiltrating lymphocytes (TILs) are independent prognostic factors in systemically untreated early-stage triple-negative breast cancer (TNBC). Other immune biomarkers including CD8, CD20, programmed cell death-ligand 1 (PD-L1), and tertiary lymphoid structures (TLS) also reported to be associated with prognosis. However, whether combining other TILs would allow for further stratification is unknown. Methods We retrospectively analyzed 125 patients TNBC not...
Chemotherapy and radiotherapy were postulated to induce an inflamed tumour microenvironment. We aimed evaluate the effects of adjuvant chemotherapy/radiotherapy on tumour-infiltrating lymphocytes (TILs) programmed death-ligand 1 (PD-L1) expression in metastatic breast cancer.We identified paired primary tumours 85 patients with cancer. Stromal TILs assessed according international guidelines. PD-L1 was evaluated using VENTANA SP142 assay.TILs significantly lower than (12.2 vs. 8.3%, p =...